Cefpodoxime Proxetil Granule, For Suspension
Product Images NDC 65862-141

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cefpodoxime Proxetil (NDC 65862-141). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label-principal Display Panel (100 mg/5 mL (100 mL Bottle))

Package Label-principal Display Panel (100 mg/5 mL (100 mL Bottle))
This is a description of a medication called Cefpodoxime Proxetil, intended for oral consumption only. The medication comes in the form of a 100 mL suspension, and contains cefpodoxime proxetil USP equivalent to 50 mg of the active ingredient per 5 mL of suspension. The usual recommended dosage is included in the package insert for Dosage and Administration. The medication should not be injected, and must be kept out of reach of children. The granules should be stored at room temperature before they are mixed with distilled water to create the suspension. The constituted mixture must then be stored in the refrigerator. Instructions on how to mix the granules and distilled water are included. The mixture can be used for a period of 14 days, after which any unused portions must be discarded. This medication is distributed by Aurobindo Pharma USA, Inc. and is made in India.*
FDA Label Image

Package Label-principal Display Panel (100 mg/5 mL Carton Label)

Package Label-principal Display Panel (100 mg/5 mL Carton Label)
Cefpodoxime Proxetil for Oral Suspension is a medication that comes in a 100 mL bottle and is only available with a prescription. The medication should not be injected and should be kept out of the reach of children. The package insert provides information on how to use the medication, including dosage and administration instructions. The granules should be stored at controlled room temperature, and the constituted suspension should be stored in a refrigerator. The medication should be shaken well before using, and any unused portion should be discarded after 14 days. The medication is distributed by Aurobindo Pharma USA, Inc. and is made in India.*
FDA Label Image

Package Label-principal Display Panel (50 mg/5 mL (100 mL Bottle))

Package Label-principal Display Panel (50 mg/5 mL (100 mL Bottle))
Cefpodoxime Proxetil is an oral suspension medication used for treating infections caused by bacteria, such as pneumonia and bronchitis. Each 5 mL of suspension constitutes 100 mg of cefpodoxime proxetil. The standard dosage information is written on the package insert. It is not suitable for injection. Before reconstitution, the desiccant capsule should be removed. After mixing with distilled water, the suspension can be used for 14 days and needs to be kept in the refrigerator. It is recommended to discard the unused portion after 14 days of usage. The medication should be kept out of reach of children. It is made in India and distributed in the USA under the brand name Aurobindo by Aurobindo Pharma USA, Inc.*
FDA Label Image

Package Label-principal Display Panel (50 mg/5 mL Carton Label)

Package Label-principal Display Panel (50 mg/5 mL Carton Label)
This is a description of the drug Cefpodoxime Proxetil for Oral Suspension, USP, containing 100 mg/5ml of cefpodoxime. The usual dosage is provided in the package insert. The text cautions against injection and provides instructions for storage before and after constitution. The drug can be used for 14 days, after which the unused portion should be discarded. The drug is distributed by Aurobindo Pharma USA, Inc.*
FDA Label Image

Chemical Structure (Cefpodoxime Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.